Skip to content

The Muscle Monitor: Early Skeletal Muscle Indicators of Insulin Resistance and Cardiometabolic Risk

The Muscle Phenotype and Cardiometabolic Health Monitoring Project

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07678736
Acronym
MUSCLE MONITOR
Enrollment
250
Registered
2026-07-01
Start date
2025-05-19
Completion date
2046-12-31
Last updated
2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiometabolic Risk Factors, Insulin Resistance, Insulin Resistance and Type 2 Diabetes, Muscle Fiber Type, Physical Activity

Keywords

Insulin sensitivity, Skeletal muscle, Physical activity

Brief summary

Insulin resistance is an early etiological factor in the development of type-2 diabetes (T2D), which constitutes a large societal health burden with an expected additional rise in the years to come. Skeletal muscle is the body's largest lean tissue mass and the major site of glucose disposal in response to insulin stimulation. Prior studies have suggested that a fast skeletal muscle phenotype, including a predominant fast muscle fiber composition, reduced capillary density, low fat oxidation and muscle oxidative capacity may be implicated in insulin resistance and TD2 development. However, key questions pertain in relation to the cause and effect of these relationships as well as the interaction with potential confounders and effect-modifiers including life-style factors (e.g. diet and physical activity levels) and general participant characteristics (e.g. body composition and training status). In the present project, we therefore aim to derive muscle fiber type and extensively map the proteomic signature of the early stages of insulin resistance in a large cross-sectional study using a young and apparently healthy cohort prior to T2D development, including a thorough participant characterization. We will recruit \ 250 participants (men and women) in the age of 20-30 years and conduct extensive phenotyping and tissue sampling across one laboratory-based test day and a scan visit, as well as measurements of physical activity level and glucose handling in free-living conditions with wearable sensors. The study has a longitudinal aspect as participants will be re-invited at 5-year intervals for up to 20 years to delineate the trajectory of metabolic health in relation to muscle phenotype measures. The results of the project are expected to lead to significant advancements in our understanding of the importance of muscle phenotype for early-stage insulin resistance and metabolic health trajectories. Such understanding has potentially important clinical implications, as it can open new avenues for targeted interventions and individualized early preventive strategies to counter or delay the progression of insulin resistance and associated metabolic and cardiovascular disorders.

Detailed description

The project is composed of 1) a screening visit to determine study eligibility, 2) a main test day in the lab, 3) 10 days of physical activity tracking and continuous glucose monitoring in free-living conditions and 4) a scan visit including a whole-body MRI scan and lower leg pQCT scan. For the main lab visit the participants will arrive in the morning after an overnight fast. This visit includes measurements of anthropometrics, resting metabolic rate, resting heart rate + heart rate variability, arterial stiffness, intima media thickness, as well as blood pressure obtained in the supine position. In addition, a fasting blood sample will be obtained followed by a 2-h glucose tolerance test with concomitant questionnaires provided in writing on basic demographics, physical activity level, sleep, stress and mental health. Two thigh muscle biopsies and a subcutaneous adipose tissue fat sample from the abdominal region will be obtained, while maximal voluntary knee-extensor contraction torque and rate of force development will be measured. Lastly, cycling-based assessments of maximal fat oxidation rate, peak power and maximal oxygen uptake will be assessed using indirect calorimetry including capillary lactate samples. The scan visit will consist of an MRI whole-body scan, soleus and gastrocnemius 1H-MRS and a pQCT bone scan of the lower limb at 4% and 66% of the total bone length. The objective measurements of physical activity levels and glucose-handling capacity will be performed for 10 days in free-living conditions using feasibly worn sensors (continuous glucose monitor and thigh-worn accelerometer). During this time, a food dairy needs to be filled in during two week days and one weekend day to estimate the habitual food intake. A standardized evening meal will be provided prior to the laboratory-based test day and a standardized lunch meal served during the testing day.

Interventions

None listed

Sponsors

University Ghent
Lead SponsorOTHER
University Hospital, Ghent
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 30 Years

Inclusion criteria

* Sex: Males and females * Age: 20-30 years * BMI \<35 * Healthy (no diagnosed chronic disease)

Exclusion criteria

* Chronic disease deemed to affect study outcomes * Disease that increase haemorrhage risk * Daily intake of medication that could confound study outcomes * Regular smokers * Active pregnancy * Immobilization (inactivity due to injury or illness, e.g. cast or brace) for more than a week in the month prior to the study or for more than 4 weeks in the past 6 months prior to the study * Very high structured physical exercise level (\>10 h/week). * Participants not willing to adhere to standardized meal prescriptions included in the study protocols will also be excluded (due to e.g. allergies or specific dietary preferences)

Design outcomes

Primary

MeasureTime frameDescription
Whole-body insulin sensitivityAt baseline and at 5-year intervals for up to 20 yearsThe Matsuda index derived from an oral glucose tolerance test

Secondary

MeasureTime frameDescription
Skeletal muscle fiber typeAt baseline and at 5-year intervals for up to 20 yearsSkeletal muscle fiber type assessed using SDS page
Molecular skeletal muscle profileAt baseline and at 5-year intervals for up to 20 yearsMolecular profiling of skeletal muscle tissue, including proteomic and related pathway-level analyses relevant to metabolic function.
MRI-derived muscle and fat volumesAt baseline and at 5-year intervals for up to 20 yearsWhole-body MRI-derived muscle and fat volumes at the total and regional body level
MRI derived tissue fat infiltrationAt baseline and at 5-year intervals for up to 20 yearsWhole-body MRI-derived tissue fat infiltration in the liver, intermuscular and intramuscular area
Physical activity levelAt baseline and at 5-year intervals for up to 20 yearsAccelerometer-based physical activity levels
HOMA-IRAt baseline and at 5-year intervals for up to 20 yearsHomeostatic Model Assessment of Insulin Resistance based on fasted blood sampling
Cardiorespiratory fitnessAt baseline and at 5-year intervals for up to 20 yearsMaximal oxygen uptake assessed using indirect calorimetry during incremental cycling
Muscle strengthAt baseline and at 5-year intervals for up to 20 yearsMaximal voluntary isometric contraction torque assessed in a dynamometer
Free-living glycaemic controlAt baseline and at 5-year intervals for up to 20 yearsContinuous glucose monitoring-derived glycaemic metrics during free-living conditions
Dietary intakeAt baseline and at 5-year intervals for up to 20 yearsDietary intake assessed using repeated 24-hour food diaries and food frequency questionnaires, including estimates of energy intake and macronutrient composition.
Subcutaneous adipose tissue phenotypingAt baseline and at 5-year intervals for up to 20 yearsProteomics derived measures of adipose tissue phenotype
Maximal fat oxidation rateAt baseline and at 5-year intervals for up to 20 yearsMaximal fat oxidation rate obtained using indirect calorimetry during incremental cycling
Pulsewave velocityAt baseline and at 5-years intervals for up to 20 yearsCarotid-femoral pulsewave velocity measured using Doppler echocardiography with ECG gating
Resting heart rateAt baseline and at 5-year intervals for up to 20 yearsResting heart rate assessed using a chest-worn heart rate monitor
Heart rate variabilityAt baseline and at 5-year intervals for up to 20 yearsHeart rate variability assessed using a chest-worn heart rate monitor

Countries

Belgium

Contacts

CONTACTEline Lievens, Professor
eline.lievens@ugent.be00320478312585
CONTACTJeppe Foged Vigh-Larsen, PhD
jeppefoged.vighlarsen@ugent.be004529870635

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026